Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Annals of Oncology

• Publication date

  2010-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdp452PMID 19875757
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular endothelial growth factor (VEGF) gene (VEGFA) polymorphism can predict the prognosis in acute myeloid leukaemia patients

  2007cited by this paper
• Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors

  2007cited by this paper
• New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance

  2006cited by this paper
• Vascular endothelial growth factor (VEGF)-Receptor2: its biological functions, major signaling pathway, and specific ligand VEGF-E.

  2006cited by this paper
• DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption.

  2006cited by this paper
• Association between genetic variations of vascular endothelial growth factor receptor 2 and atopy in the Korean population.

  2006cited by this paper
• Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics.

  2005cited by this paper
• Elevated plasma levels of vascular endothelial growth factor is associated with marked splenomegaly in chronic myeloid leukemia

  2005cited by this paper
• Title : DNA SEQUENCE VARIATION IN THE PROMOTER REGION OF THE VEGF GENE : IMPACTS ON VEGF GENE EXPRESSION AND MAXIMAL OXYGEN CONSUMPTION

  2005cited by this paper
• Bevacizumab: antiangiogenic cancer therapy.

  2005cited by this paper
• Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2

  2004cited by this paper
• Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.

  2004cited by this paper
• Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.

  2004cited by this paper
• Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.

  2004cited by this paper
• VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer.

  2004cited by this paper
• Angiogenic Factors Reconstitute Hematopoiesis by Recruiting Stem Cells from Bone Marrow Microenvironment

  2003cited by this paper
• Polycystic Ovary Syndrome in Adolescence

  2003cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Effects of angiogenic regulators on in vitro proliferation and cytokine secretion by native human acute myelogenous leukemia blasts

  2003cited by this paper
• Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.

  2003cited by this paper
• Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study

  2003cited by this paper
• Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter.

  2003cited by this paper
• Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.

  2002cited by this paper
• Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia

  2002cited by this paper
• Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.

  2002cited by this paper
• Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

  2002cited by this paper
• Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants

  2002cited by this paper
• BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

  2002cited by this paper
• A new statistical method for haplotype reconstruction from population data.

  2001cited by this paper
• Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells

  2001cited by this paper
• Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes.

  2001cited by this paper
• Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

  2001cited by this paper
• Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes.

  2000cited by this paper
• A Common 936 C/T Mutation in the Gene for Vascular Endothelial Growth Factor Is Associated with Vascular Endothelial Growth Factor Plasma Levels

  2000cited by this paper
• Evidence of increased angiogenesis in patients with acute myeloid leukemia.

  2000cited by this paper
• Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production.

  2000cited by this paper
• The molecular biology of chronic myeloid leukemia.

  2000cited by this paper
• Evidence from a leukaemia model for maintenance of vascular endothelium by bone-marrow-derived endothelial cells.

  2000cited by this paper
• Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.

  1999cited by this paper
• Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene.

  1999cited by this paper
• KDR receptor: a key marker defining hematopoietic stem cells.

  1999cited by this paper
• Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.

  1997cited by this paper
• The biology of vascular endothelial growth factor.

  1997cited by this paper
• Vascular endothelial growth factor and its receptors.

  1996cited by this paper
• Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic Agent (*)

  1996cited by this paper
• Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3.

  1996cited by this paper
• A bootstrap resampling procedure for model building: application to the Cox regression model.

  1992cited by this paper
• The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing.

  1991cited by this paper
• 'Drug holidays' in the treatment of Parkinson's disease. A brief review.

  1985cited by this paper

• Genetic and pharmacokinetic factors associated with imatinib-induced toxicities in gastrointestinal stromal tumors

  2025cites this paper
• The synergistic effect of HIF-1α, VEGFA and VEGFR2 gene polymorphisms in the pathogenesis of acute myeloid leukemia

  2025cites this paper
• Evaluation of expression profile of patients with acute myeloid leukemia in response to Azacitidine with biological system approach.

  2023cites this paper
• Gene polymorphisms of VEGF and KDR are associated with initial fast peritoneal solute transfer rate in peritoneal dialysis

  2022cites this paper
• Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features

  2022cites this paper
• Topical application of imatinib mesylate suppresses vitamin D3 analog‐induced dermatitis in Balb/c mice

  2022cites this paper
• Biomarkers Associated with Regorafenib First-Line Treatment Benefits in Metastatic Colorectal Cancer Patients: REFRAME Molecular Study

  2021cites this paper
• Association of DNA repair gene XPC Ala499Val (rs2228000 C>T) and Lys939Gln (rs2228001 A>C) polymorphisms with the risk of chronic myeloid leukemia: A case–control study in a South Indian population

  2021cites this paper
• Association of VEGFA gene polymorphisms with susceptibility to non-Hodgkin's lymphoma: Evidences from population-based and in silico studies

  2020cites this paper
• Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies

  2020cites this paper
• Vascular endothelial growth factor gene polymorphism in Egyptian patients with B-cell chronic lymphocytic leukemia

  2020cites this paper
• Neue Anwendungen der DNA-Analyse: Chancen und Risiken. Interdisziplinäre Technikfolgenabschätzung

  2020cites this paper
• Vascular Endothelial Growth Factor Receptor 2

  2020influential citation
• Impact of single nucleotide polymorphisms in the VEGFR2 gene on endothelial cell activation under non-uniform shear stress

  2019cites this paper
• Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.

  2019cites this paper
• KDR (VEGFR2) Genetic Variants and Serum Levels in Patients with Rheumatoid Arthritis

  2019cites this paper
• HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia

  2018cites this paper
• Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.

  2017cites this paper
• Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia

  2017cites this paper
• Determination of VEGFR-2 (KDR) 604A>G Polymorphism in Pancreatic Disorders

  2017cites this paper
• Disrupting Tumor Angiogenesis and "the Hunger Games" for Breast Cancer.

  2017cites this paper
• Association between single nucleotide variants of vascular endothelial growth factor A and the risk of thyroid carcinoma and nodular goiter in a Han Chinese population

  2017cites this paper
• Genetic Variants of VEGF (rs201963 and rs3025039) and KDR (rs7667298, rs2305948, and rs1870377) Are Associated with Glioma Risk in a Han Chinese Population: a Case-Control Study

  2016cites this paper
• ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer

  2016cites this paper
• Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease

  2016cites this paper
• Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition

  2015cites this paper
• Association of Vascular Endothelial Growth Factor A (VEGFA) and its Receptor (VEGFR2) Gene Polymorphisms with Risk of Chronic Myeloid Leukemia and Influence on Clinical Outcome

  2015influential citation
• Impact of VEGF, VEGFR, PDGFR, HIF and ERCC1 gene polymorphisms on thymic malignancies outcome after thymectomy

  2015cites this paper
• Joint Effect of Urinary Total Arsenic Level and VEGF-A Genetic Polymorphisms on the Recurrence of Renal Cell Carcinoma

  2015cites this paper
• Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia

  2015cites this paper
• Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy

  2014cites this paper
• Vascular Endothelial Growth Factor A (VEGFA) Gene Polymorphisms Have an Impact on Survival in a Subgroup of Indolent Patients with Chronic Lymphocytic Leukemia

  2014cites this paper
• NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status

  2014cites this paper
• Genetic Variants Involved in Intracellular Mechanisms of Chemoresistance to Anticancer Drugs Due to Changes in the Effect on Their Molecular Targets

  2013cites this paper
• International SportMed Journal Original research article The VEGFR2 gene His472Gln polymorphism in Polish endurance athletes

  2013cites this paper
• Association between Genetic Variants of the VEGFR-2 Gene and the Risk of Developing Endometriosis in Northern Chinese Women

  2013cites this paper
• A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528

  2013cites this paper
• Antibody-directed double suicide gene therapy targeting of MUC1- positive leukemia cells in vitro and in vivo.

  2013cites this paper
• High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients

  2013cites this paper
• VEGFR-2, CXCR-2 and PAR-1 germline polymorphisms as predictors of survival in pancreatic carcinoma.

  2013cites this paper
• Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.

  2012cites this paper
• Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis

  2012cites this paper
• VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma

  2012cites this paper
• Targeting angiogenesis as a promising modality for the treatment of prostate cancer.

  2012cites this paper
• Vascular Endothelial Growth Factor Receptor 2 Gene Polymorphisms as Predictors for Tumor Recurrence and Overall Survival in Non-Small-Cell Lung Cancer

  2012cites this paper
• Common polymorphisms in angiogenesis.

  2012cites this paper
• Bevacizumab — eine endlose Geschichte

  2012cites this paper
• Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer

  2012cites this paper
• VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration

  2011cites this paper
• Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib).

  2011cites this paper
• Vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (NOS3) polymorphisms are associated with high relapse risk in childhood acute lymphoblastic leukemia (ALL).

  2010cites this paper
• Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.

  2010cites this paper